000143223 001__ 143223
000143223 005__ 20240229112545.0
000143223 0247_ $$2doi$$a10.1186/s13058-019-1119-y
000143223 0247_ $$2pmid$$apmid:30867002
000143223 0247_ $$2pmc$$apmc:PMC6416887
000143223 0247_ $$2ISSN$$a1465-5411
000143223 0247_ $$2ISSN$$a1465-542X
000143223 0247_ $$2altmetric$$aaltmetric:58819602
000143223 037__ $$aDKFZ-2019-00822
000143223 041__ $$aeng
000143223 082__ $$a610
000143223 1001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b0$$eFirst author$$udkfz
000143223 245__ $$aParity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies.
000143223 260__ $$aLondon$$bBioMed Central$$c2019
000143223 3367_ $$2DRIVER$$aarticle
000143223 3367_ $$2DataCite$$aOutput Types/Journal article
000143223 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1554211938_30178
000143223 3367_ $$2BibTeX$$aARTICLE
000143223 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143223 3367_ $$00$$2EndNote$$aJournal Article
000143223 520__ $$aEpidemiologic data suggest that parity increases risk of hormone receptor-negative breast cancer and that breastfeeding attenuates this association. Prospective data, particularly on the joint effects of higher parity and breastfeeding, are limited.We investigated parity, breastfeeding, and breast cancer risk by hormone-receptor (estrogen (ER) and progesterone receptor (PR)) and molecular subtypes (luminal A, luminal B, HER2-enriched, and basal-like) in the Nurses' Health Study (NHS; 1976-2012) and NHSII (1989-2013). A total of 12,452 (ER+ n = 8235; ER- n = 1978) breast cancers were diagnosed among 199,514 women. We used Cox proportional hazards models, adjusted for breast cancer risk factors, to calculate hazard ratios (HR) and 95% confidence intervals (CI).Parous women had lower risk of ER+ breast cancer (vs. nulliparous, HR = 0.82 [0.77-0.88]); no association was observed for ER- disease (0.98 [0.84-1.13]; Phet = 0.03). Among parous women, breastfeeding was associated with lower risk of ER- (vs. never 0.82 [0.74-0.91]), but not ER+, disease (0.99 [0.94-1.05]; Phet < 0.001). Compared to nulliparous women, higher parity was inversely associated with luminal B breast cancer regardless of breastfeeding (≥ 3 children: ever breastfed, 0.78 [0.62-0.98]; never breastfed, 0.76 [0.58-1.00]) and luminal A disease only among women who had breastfed (≥ 3 children, 0.84 [0.71-0.99]). Basal-like breast cancer risk was suggestively higher among women with higher parity who never breastfed; associations were null among those who ever breastfed.This study provides evidence that breastfeeding is inversely associated with hormone receptor-negative breast cancers, representing an accessible and cost-effective risk-reduction strategy for aggressive disease subtypes.
000143223 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143223 588__ $$aDataset connected to CrossRef, PubMed,
000143223 7001_ $$aSisti, Julia$$b1
000143223 7001_ $$aChai, Boyang$$b2
000143223 7001_ $$aCollins, Laura C$$b3
000143223 7001_ $$aRosner, Bernard$$b4
000143223 7001_ $$aHankinson, Susan E$$b5
000143223 7001_ $$aTamimi, Rulla M$$b6
000143223 7001_ $$aEliassen, A Heather$$b7
000143223 773__ $$0PERI:(DE-600)2041618-0$$a10.1186/s13058-019-1119-y$$gVol. 21, no. 1, p. 40$$n1$$p40$$tBreast cancer research$$v21$$x1465-542X$$y2019
000143223 909CO $$ooai:inrepo02.dkfz.de:143223$$pVDB
000143223 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143223 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143223 9141_ $$y2019
000143223 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBREAST CANCER RES : 2017
000143223 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143223 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143223 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143223 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143223 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143223 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143223 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143223 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143223 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143223 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000143223 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000143223 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review
000143223 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000143223 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBREAST CANCER RES : 2017
000143223 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000143223 980__ $$ajournal
000143223 980__ $$aVDB
000143223 980__ $$aI:(DE-He78)C020-20160331
000143223 980__ $$aUNRESTRICTED